Profile of betrixaban and its potential in the prevention and treatment of venous thromboembolism

  title={Profile of betrixaban and its potential in the prevention and treatment of venous thromboembolism},
  author={Noel C Y Chan and Vinai C. Bhagirath and John W. Eikelboom},
  booktitle={Vascular health and risk management},
Venous thromboembolism (VTE), which includes deep vein thrombosis and pulmonary embolism, is a common and potentially preventable cause of morbidity and mortality. Unfractionated heparin, low-molecular-weight heparin, and warfarin have been the cornerstone of VTE prevention and treatment but are being replaced by recently approved non-vitamin K antagonist oral anticoagulants (NOACs): dabigatran, rivaroxaban, apixaban, and edoxaban. The NOACs are at least as effective and as safe as heparins and… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 3 times over the past 90 days. VIEW TWEETS
18 Citations
39 References
Similar Papers


Publications citing this paper.
Showing 1-10 of 18 extracted citations


Publications referenced by this paper.
Showing 1-10 of 39 references

Animal models of thrombosis help predict the human therapeutic concentration of PRT54021, a potent oral factor Xa inhibitor

  • K Abe, G Siu, S Edwards
  • Blood
  • 2006
Highly Influential
5 Excerpts

Metabolism and disposition of betrixaban and its lack of interaction with major CYP enzymes

  • A Hutchaleelaha, C Ye, Y Song, T Lorenz, D Gretler, JL. Lambing
  • ASH Annu Meet Abstr
  • 2012
Highly Influential
3 Excerpts

Similar Papers

Loading similar papers…